A single-centre, prospective, longitudinal study to evaluate the clinical response and association of drug exposure with toxicity in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 02 Dec 2015 New trial record